Biotech, Not AI, Powers San Francisco’s Market Revival

San Francisco, long known for its cultural vibrancy and innovation, is now experiencing an unexpected financial renaissance—driven not by artificial intelligence, but by biotechnology. As investors reassess the city’s post-pandemic potential, a new class of local stocks is leading the charge, redefining the investment narrative for one of America’s most iconic cities.

In a recent performance screen conducted by CNBC’s Power Lunch team using data from S&P Capital IQ and FactSet, a surprising trend emerged: biotech companies headquartered in San Francisco have outperformed expectations, generating significant returns over the past three months. These firms, many focused on advancing treatments for chronic and rare diseases, have become some of the most profitable bets in the region.

While the broader tech sector remains in flux amid tightening margins and shifting investor sentiment, biotech’s renewed momentum highlights the enduring value of science-based innovation — a sector less vulnerable to cyclical hype and more tethered to long-term demand in healthcare and therapeutics.

Nektar Therapeutics and the Rise of Medical Innovation

At the top of the leaderboard is Nektar Therapeutics (NKTR), whose shares have soared roughly 150% in the past 90 days. The company’s progress in developing new treatments for dermatitis and alopecia areata has reignited investor optimism. According to FactSet, nine analysts tracking Nektar have issued an average price target of $93.60, representing nearly 50% upside potential from current levels.

“Nektar’s resurgence underscores how innovation in targeted therapeutics can deliver exponential returns, especially when coupled with a robust clinical pipeline,” said Liam Chen, an equity analyst specializing in healthcare at Polaris Partners. “Investors are seeking growth stories grounded in science rather than speculative narratives.”

Joining Nektar in the biotech rally are Maze Therapeutics, Olema Pharmaceuticals, Cytokinetics, and Septerna, all of which have benefited from rising institutional inflows into the healthcare sector as investors look for defensive yet high-growth opportunities amid a volatile macroeconomic backdrop.

Sunrun, The RealReal, and Planet Labs Add to the Mix

Beyond biotech, other San Francisco-based companies have also enjoyed impressive rebounds. Sunrun (RUN), a leading residential solar and storage provider, has doubled in value over the last quarter despite enduring significant volatility earlier in the year. CEO Mary Power recently noted that the firm’s expansion into battery storage solutions has created a “new phase of profitability,” aligning with growing U.S. demand for renewable energy amid high electricity costs.

Meanwhile, The RealReal (REAL) has captured renewed consumer interest in the luxury resale market. The company’s stock is now trading just above its median analyst price target, suggesting the rally may be losing steam — but the sustainability-driven business model continues to attract long-term interest.

Planet Labs (PL), which brands itself as an “earth intelligence” company, has seen its shares nearly double over the past year, driven by surging demand for satellite imagery and analytics across industries from agriculture to defense.

Together, these companies showcase San Francisco’s ability to reinvent itself economically, even as the city continues to navigate social and infrastructural challenges.

A City and Market in Reinvention

San Francisco’s market renaissance mirrors the city’s broader recovery narrative — resilient, surprising, and distinctly innovative. While artificial intelligence remains a defining theme across Silicon Valley, it is biotech, renewable energy, and space intelligence that are currently fueling the city’s investment story.

Analysts suggest that this diversification is critical to the region’s long-term stability. “What’s happening in San Francisco reflects a broader shift in investor behavior,” said Marissa Alonzo, senior strategist at Horizon Research. “We’re seeing a pivot from hype-driven growth to mission-driven profitability.”

As CNBC’s Power Lunch broadcasts from the Bay this week, the spotlight is once again on San Francisco — a city proving that even after years of turbulence, innovation still drives its pulse, both culturally and economically.